The CONCEPTT and Swedish studies of CGM in pregnancy demonstrated the gap that currently exists between the CGM TIR targets and the realities of safely achieving 70% TIR with no more than 25% TAR in type 1 diabetes pregnancy.7,13 In both studies, women using multiple daily injections or insulin pump therapy and with access to flash or CGM only achieved the pregnancy glucose targets during the third trimester. This evidence concerns the gene INS and type 1 diabetes mellitus.